LENZ Therapeutics, Inc. (LENZ)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.40
- As of
Kresmion compiles this page from LENZ's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
LENZ Therapeutics, Inc. (LENZ): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
See the full LENZ dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LENZ on one page. Preview it with sample data, then open it live with a free account.
Preview the LENZ dossierActive signals for LENZ
- highCONSENSUS_BUY
3 tracked funds increased LENZ this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 7.0%, EPS $-1.02 vs $-1.0962 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +342% to LENZ (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +74% to LENZ (2026Q2)
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in LENZ
FREE, NO ACCOUNT
Every signal on LENZ, as it fires
You are seeing 5 of 11 signals recorded on LENZ since 2026-06-05.
The five above landed across 3 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LENZ (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 52635N103 · 2026Q2 | $8.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 52635N103 · 2026Q2 | $2.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 52635N103 · 2026Q2 | $1.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 52635N103 · 2026Q2 | $401K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LENZ
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LENZ against its peers
LENZ's operating margin of -477.5% ranks in the 41st percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2025-12-31.
| Metric | LENZ | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 19.1M USD | 2.0M USD | 61 | 13 |
| Operating margin | -477.5% | -281.7% | 41 | 10 |
| Net margin | -430.3% | -253.7% | 41 | 10 |
| Return on equity | -28.9% | -117.6% | 85 | 16 |
| 1 year | -91.2% | -38.3% | 8 | 18 |
Peers (21): PYPD, GNLX, FHTX, CLLS, VANI, ANIX, SPRB, VXRT, HURA, UNCY, SMNR, COYA, HUMA, ARMP, MIST, BDTX, NERV, ATRA, INO, RANI, PLYX. Left out: TNXP (no annual filing), CNXU (no annual filing), SPRC (period gap), HSTC (period gap). Fiscal periods ending between 2025-10-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (LENZ: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LENZ on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LENZ for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.